Učitavanje...
Recent updates on CAR T clinical trials for multiple myeloma
Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturati...
Spremljeno u:
| Izdano u: | Mol Cancer |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6829852/ https://ncbi.nlm.nih.gov/pubmed/31684964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-019-1092-1 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|